» Articles » PMID: 18217967

Serous Borderline Ovarian Tumors in Long-term Culture: Phenotypic and Genotypic Distinction from Invasive Ovarian Carcinomas

Overview
Date 2008 Jan 26
PMID 18217967
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Serous borderline ovarian tumors (SBOTs) are differentiated, slow growing, noninvasive, and have a better prognosis than their invasive counterparts, but recurrence and progression to invasive carcinomas are common, and unlike high-grade serous carcinomas, they tend to be nonresponsive to chemotherapy. However, due to a lack of culture systems and animal models, information about the properties of SBOT and their changes with neoplastic progression is extremely limited. Our objective was to establish a cell culture model for SBOTs and to characterize their phenotype and genotype. We compared cultures derived from two SBOTs, one of which was a short-term culture containing a BRAF mutation but few other cytogenetic changes while the other culture developed into a spontaneously immortalized permanent cell line and had numerical and structural chromosomal abnormalities but lacked RAS/BRAF mutations. Both cultures formed whorl-like epithelial colonies and resembled low-grade invasive carcinomas by their secretion of CA125 and oviduct-specific glycoprotein, production of matrix metalloproteinases, E-cadherin expression, and telomerase activity. Other characteristics associated with neoplastic transformation, including invasiveness, anchorage-independent growth, and tumorigenicity, were not observed. Importantly, cell motility was reduced in both lines, likely contributing to the lack of invasiveness. The results reveal a striking phenotypic similarity between the two cell lines, regardless of their cytogenetic diversity, which suggests that their characteristic phenotype is regulated to a large degree by epigenetic and environmental factors. In conclusion, we have established the first permanent SBOT cell line, which provides a new model to elucidate the undefined relationship of SBOTs to invasive ovarian carcinomas.

Citing Articles

Molecular changes driving low-grade serous ovarian cancer and implications for treatment.

Kelliher L, Yoeli-Bik R, Schweizer L, Lengyel E Int J Gynecol Cancer. 2024; 34(10):1630-1638.

PMID: 38950921 PMC: 11503204. DOI: 10.1136/ijgc-2024-005305.


Molecular landscape of borderline ovarian tumours: A systematic review.

Sadlecki P, Walentowicz-Sadlecka M Open Med (Wars). 2024; 19(1):20240976.

PMID: 38859878 PMC: 11163159. DOI: 10.1515/med-2024-0976.


Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.

Fernandez M, DiMattia G, Dawson A, Bamford S, Anderson S, Hennessy B Am J Cancer Res. 2016; 6(10):2235-2251.

PMID: 27822414 PMC: 5088288.


CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells.

Qiu X, Klausen C, Cheng J, Leung P Cell Death Dis. 2015; 6:e1864.

PMID: 26313915 PMC: 4558516. DOI: 10.1038/cddis.2015.229.


Advanced stage micropapillary serous borderline ovarian tumor in a postmenopausal woman: a case report.

Gungor T, Kaba M, Baser E, Yalcin H, Bayramoglu H, Besli M J Turk Ger Gynecol Assoc. 2014; 13(3):208-11.

PMID: 24592040 PMC: 3939243. DOI: 10.5152/jtgga.2012.30.